EICHORCondition: Esophageal Squamous Cell Carcinoma · Chemotherapy Effect · DNA Methylation · Sponsor: City of Hope Medical Center
Interested? Contact the study team ↓
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.
This description comes directly from the study's public registry record.
Ajay Goel, PhD · 6262183452 · AJGOEL@COH.ORG
Koichi Takiguchi, PhD · 6262183452 · ktakiguchi@coh.org
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Patients who had histologically confirmed esophageal squamous cell carcinoma. 2. Patients who had undergone chemotherapy. 3. Patients receiving initial chemotherapy 4. Written informed consent following full study information is provided to the patient. Exclusion Criteria: 1. Patients for whom a preoperative biopsy sample cannot be obtained 2. Patients who cannot assess at 2 months later after chemotherapy. 3. Patients with multiple cancers.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Yamanashi Universiy | Chūō, Yamanashi, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06490003